Department of Pulmonology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Respiratory Disease Center, Yokohama City University Medical Center, Yokohama, Japan.
Thorac Cancer. 2020 Apr;11(4):983-992. doi: 10.1111/1759-7714.13351. Epub 2020 Feb 17.
Currently, anticancer immunotherapy based on PD-1/PD-L1 blockade with immune checkpoint inhibitors (ICIs) is being used as a standard therapy for non-small cell lung cancer (NSCLC). However, more effective treatments are required as these tumors are often resistant and refractory. Here, we aimed to determine the effects of immunomodulatory oligodeoxynucleotides (ODNs) in terms of the presence or absence of CpG motifs and the number of consecutive guanosines.
Western blots were used to measure the molecules which regulate the expression of PD-L1 in human lung cancer cell lines after incubation with several cytokines and ODNs. The expression of PD-L1 and β2-microglobulin (β2-MG) on A549 cells, and IFN-γ-induced apoptosis with ODNs were examined by flow cytometry. The relationship between IFN-γ receptor and ODN was analyzed by ELISA and immunofluorescence chemistry.
Our results verified that A-CpG ODNs suppress the upregulation of IFN-γ-induced PD-L1 and β2-MG expression. In addition, we found that ODNs with six or more consecutive guanosines (ODNs with poly-G sequences) may competitively inhibit the IFN-γ receptor and abolish the effect of IFN-γ, thereby suppressing apoptosis and indoleamine 2,3-dioxygenase 1 expression in human lung cancer cells. The tumor microenvironment regulates whether this action will promote or suppress tumor immunity. Thus, in immunotherapy with CpG ODNs, it is essential to consider the effect of ODNs with poly-G sequences.
This study suggests that ODNs containing six or more consecutive guanosines may inhibit the binding of IFN-γ to IFN-γ receptor. However, it does not directly show that ODNs containing six or more consecutive guanosines competitively inhibit the IFN-γ receptor, and further studies are warranted to confirm this finding.
Significant findings of the study: Oligodeoxynucleotides with a contiguous sequence of six or more guanosines may competitively inhibit the IFN-γ receptor and abolish the action of IFN-γ. This may suppress IFN-γ-induced apoptosis and indoleamine-2,3-dioxygenase-1 expression in human lung cancer cells.
A-CpG and poly-G ODN may overcome tolerance if the cause of ICI tolerance is high IDO expression. However, IFN-γ also has the effect of suppressing apoptosis of cancer cells, and it is necessary to identify the cause of resistance.
目前,基于免疫检查点抑制剂(ICIs)的 PD-1/PD-L1 阻断的抗癌免疫疗法被用作非小细胞肺癌(NSCLC)的标准治疗方法。然而,由于这些肿瘤通常具有耐药性和难治性,因此需要更有效的治疗方法。在这里,我们旨在确定免疫调节寡核苷酸(ODN)的作用,包括是否存在 CpG 基序和连续鸟嘌呤的数量。
用几种细胞因子和 ODN 孵育后,用 Western blot 测定调节人肺癌细胞系中 PD-L1 表达的分子。通过流式细胞术检查 A549 细胞上的 PD-L1 和 β2-微球蛋白(β2-MG)表达以及 ODN 诱导的 IFN-γ 诱导的细胞凋亡。通过 ELISA 和免疫荧光化学分析 IFN-γ 受体与 ODN 的关系。
我们的结果证实 A-CpG ODN 可抑制 IFN-γ 诱导的 PD-L1 和 β2-MG 表达的上调。此外,我们发现具有六个或更多连续鸟嘌呤的 ODN(具有聚 G 序列的 ODN)可能竞争性抑制 IFN-γ 受体并消除 IFN-γ 的作用,从而抑制人肺癌细胞中的细胞凋亡和吲哚胺 2,3-双加氧酶 1 表达。肿瘤微环境调节这种作用是促进还是抑制肿瘤免疫。因此,在使用 CpG ODN 的免疫治疗中,必须考虑具有聚 G 序列的 ODN 的作用。
这项研究表明,含有六个或更多连续鸟嘌呤的 ODN 可能抑制 IFN-γ 与 IFN-γ 受体的结合。然而,它并没有直接表明含有六个或更多连续鸟嘌呤的 ODN 竞争性抑制 IFN-γ 受体,需要进一步的研究来证实这一发现。
研究的重要发现:具有连续六个或更多鸟嘌呤的寡脱氧核苷酸可能竞争性抑制 IFN-γ 受体并消除 IFN-γ 的作用。这可能抑制 IFN-γ 诱导的人肺癌细胞凋亡和吲哚胺 2,3-双加氧酶 1 的表达。
A-CpG 和聚 G ODN 可以克服 ICI 耐受的原因是高 IDO 表达的情况下的耐受。然而,IFN-γ 也具有抑制癌细胞凋亡的作用,有必要确定耐药的原因。